wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 201 - 250 of 363.

Medicine/Pharmacology - Life Sciences
14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem
Medicine/Pharmacology - Life Sciences
13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.
Microtechnics/Electroengineering
13.09.2017
World's largest electric vehicle
World’s largest electric vehicle
A Swiss consortium of companies is constructing the largest electric vehicle in the world - in record time.
Medicine/Pharmacology
13.09.2017
Novartis’ Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx (secukinumab) is the first and only fully human IL-17A   inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis   Landmark data show that PASI 90 and PASI 100
Physics/Materials Science - Microtechnics/Electroengineering
13.09.2017
Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material
Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale.
Environment/Sustainable Development
12.09.2017
Medicine/Pharmacology - Life Sciences
12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our
Physics/Materials Science
11.09.2017
Using Mirrors to Improve the Quality of Light Particles
Using Mirrors to Improve the Quality of Light Particles
Scientists from the University of Basel's Department of Physics and the Swiss Nanoscience Institute have succeeded in dramatically improving the quality of individual photons generated by a quantum system. The scientists have successfully put a 10-year-old theoretical prediction into practice. With their paper, published recently in Physical Review X, they have taken an important step towards future applications in quantum information technology.
Medicine/Pharmacology
11.09.2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.
Medicine/Pharmacology - Media
11.09.2017
Adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relapse
Medicine/Pharmacology - Life Sciences
09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD   Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).
Medicine/Pharmacology - Earth Sciences
08.09.2017
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with previous lampalizumab trials and other intravitreal therapies Results from the second phase III study, Chro
Medicine/Pharmacology - Life Sciences
08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.
Careers/Employment - Academic Rankings
07.09.2017
Six EPFL startups are among the Swiss top 10
Six EPFL startups are among the Swiss top 10
L.E.S.S. and Flyability - two EPFL startups - are among the podium finishers in the latest TOP 100 Swiss Startups ranking, which was announced yesterday evening in Zurich.
Astronomy - Media
07.09.2017
50 years of space exploration at the University of Bern
50 years of space exploration at the University of Bern
Media releases, information for representatives of the media Media Relations (E) This year, the University of Bern celebrates 50 years of space exploration.
Physics/Materials Science - Computer Science/Telecom
07.09.2017
High-speed Quantum Memory for Photons
High-speed Quantum Memory for Photons
Physicists from the University of Basel have developed a memory that can store photons. These quantum particles travel at the speed of light and are thus suitable for high-speed data transfer.
Medicine/Pharmacology - Life Sciences
07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten
Politics - Environment/Sustainable Development
06.09.2017
Mercury: first Minamata Convention conference in Geneva
Bern, 06.09.2017 - The first Conference of the Parties to the Minamata Convention will take place from 24 to 29 September in Geneva.
Medicine/Pharmacology - Life Sciences
06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc
Physics/Materials Science - Astronomy
06.09.2017
Particle physicists on a quest for
Particle physicists on a quest for "new physics"
EPFL's physicists are moving forward in their efforts to solve the mysteries of the universe. A particle detector made up of 10,000 kilometers of scintillating fiber is under construction and will be added onto CERN's particle accelerator.
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Tuberculosis Research Against "Super Resistant Bacteria"
To fall ill from tuberculosis remains a great danger. A research team led by cell biologist Sébastien Gagneux at the Swiss Tropical and Public Health Institute (Swiss TPH) examines the antibiotic resistance mechanisms of Mycobacterium tuberculosis.
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a   There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies   Children and adolescents living with MS face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to school     PARADIGMS is a first of its kind study in pediatric MS.
Life Sciences - Environment/Sustainable Development
05.09.2017
Combating Japanese Beetles with Fungi
Zurich-Reckenholz, 05.09.2017 - In June of this year, the Japanese beetle (Popillia japonica) was detected for the first time in Switzerland, in the canton of Ticino. Considered to be a quarantine pest, it is subject to obligatory control. Agroscope researchers are testing whether this quarantine pest can be controlled with fungi that are effective against May and June beetles.
Life Sciences
05.09.2017
First Detailed Decoding of Complex Finger Millet Genome
First Detailed Decoding of Complex Finger Millet Genome
For many poor farmers in India and Africa, finger millet is a major staple food. The crop species is not only a rich source of minerals like calcium, iron, magnesium and zinc, and it contains many vitamins and essential amino acids.
Computer Science/Telecom
04.09.2017
Medicine/Pharmacology - Business/Economics
04.09.2017
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position.
Physics/Materials Science - Life Sciences
04.09.2017
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Nuclear pore complexes are tiny channels where the exchange of substances between the cell nucleus and the cytoplasm takes place. Scientists at the University of Basel report on startling new research that might overturn established models of nuclear transport regulation. Their study published in the Journal of Cell Biology reveals how shuttling proteins known as importins control the function of nuclear pores - as opposed to the view that nuclear pores control the shuttling of importins.
Environment/Sustainable Development - Earth Sciences
04.09.2017
Diverse Landscapes Are More Productive and Adapt better to Climate Change
Diverse Landscapes Are More Productive and Adapt better to Climate Change
The dramatic, worldwide loss of biodiversity is one of today's greatest environmental problems. The loss of species diversity affects important ecosystems on which humans depend. Previous research predominantly addressed short-term effects of biodiversity in small experimental plots planted with few randomly selected plant species.
Business/Economics
03.09.2017
Huge interest in the world of data
Big data, digitalisation, artificial intelligence, Internet of Things - these terms are on everybody's lips these days, but what exactly do they mean?
Environment/Sustainable Development - Event
01.09.2017
Environment/Sustainable Development - Event
01.09.2017
Medicine/Pharmacology - Business/Economics
31.08.2017
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO Presidential Symposium New data from phase III ALEX and ALUR studies provide additional evidence supporting the use o
Physics/Materials Science - Chemistry
31.08.2017
A virtual tour through "move"
Goodbye to fossil fuels, hello to renewables: Empa demonstrates how the mobility of the future can work without fossil energy in its mobility demonstrator "move".
Environment/Sustainable Development - Medicine/Pharmacology
31.08.2017
Life Sciences - Arts and Design
31.08.2017
Artists Target Ibexes
Artists Target Ibexes
The video and sound installations, sculptures, and pictures on display at the exhibition aim to build new bridges between art and the natural sciences.
Pedagogy/Education Science - Medicine/Pharmacology
31.08.2017
Children's sleep quality is related to mothers' insomnia symptoms
Children’s sleep quality is related to mothers’ insomnia symptoms
Children more often sleep poorly if their mothers suffer from insomnia symptoms. This report researchers from the University of Basel and the University of Warwick in the journal Sleep Medicine based on a study with nearly 200 school-aged children and their parents. Sleep plays an essential role for adults' and children's well-being.
Medicine/Pharmacology - Life Sciences
30.08.2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice First-in-clas
Life Sciences - Medicine/Pharmacology
30.08.2017
UZH Life Sciences Fund Invests in First Spin-off
UZH Life Sciences Fund Invests in First Spin-off
CUTISS is a company with a vision: To use personalized skin grafts to heal people all over the world with skin defects, including burn victims.
Administration/Government - Agronomy/Food Science
29.08.2017
Medicine/Pharmacology
29.08.2017
Combination Therapy to Treat Parasitic Worm Infections
Combination Therapy to Treat Parasitic Worm Infections
1.5 billion people worldwide are infected with soil-transmitted helminths, a parasitic worm infection. In the past, only two drugs have been used, increasing the risk of drug resistance. New drugs and combination therapies are thus urgently needed to fight soil-transmitted helminth infections.
Business/Economics - Computer Science/Telecom
29.08.2017
The creative data interpreters
The creative data interpreters
The ETH spin-off SpinningBytes programs software that uses machine learning not only to analyse but also to understand huge amounts of data. It enables customised solutions to be developed for numerous IT problems, and allows new insights to be gained from previously unused data. It all began a few years ago: Mark Cieliebak, Martin Jaggi and Fatih Uzdilli were computer science researchers at ETH and Zurich University of Applied Sciences (ZHAW), and published their technologies in scientific papers.
Microtechnics/Electroengineering - Computer Science/Telecom
29.08.2017
Agronomy/Food Science - Medicine/Pharmacology
29.08.2017
Obese People Lack Cells with Satiety Hormones
Obese People Lack Cells with Satiety Hormones
Individuals with severe overweight have an inhibited sense of satiation - they release fewer satiety hormones than people of normal weight. The reason: the responsible cells in the gastrointestinal tract of obese people are severely reduced. This report Swiss doctors in the journal Scientific Reports.
Mechanical Engineering/Mechanics
28.08.2017
Swissloop finishes in the top 3
Swissloop finishes in the top 3
SpaceX held its second Hyperloop pod competition yesterday in Los Angeles. The Swissloop team including ETH students achieved an outstanding third place finish.
Medicine/Pharmacology - Computer Science/Telecom
28.08.2017
"Medicine is becoming model-driven"
ETH Professor and computer scientist Joachim Buhmann works intensively on healthcare issues. In an interview with ETH News, he explains how computer models will make their way into the world of medicine, and talks about models that are so complicated that humans can no longer process them alone.